Abstract:Abstract Introduction: Hematopoietic stem cell transplant (HSCT) outcomes from unrelated donor (URD) and haploidentical donor were very close in recent years, and both could be alternative donors for recipients without siblings. But when considering donor age, especially for young recipients (≤30 years) without siblings, whether outcomes can be improved with a young URD rather than older-aged haploidentical parental donors (HPD) is still unknown. Methods: Between 2008 and 2014, a total of 156 young adult patients with hematological malignancies without sibling donors were assigned to receive URD or HPD HSCT in our center. The strategy of donor selection between URD and HPD was as follows: If an HLA suitably matched URD (≥8 of 10 matching HLA-A, -B, -C, -DRB1, and -DQB1 allele loci and ≥5 of 6 matching HLA-A, -B, and -DRB1 antigen loci) was available, patients were assigned to undergo URD-HSCT. If an HLA suitably matched URD was unavailable, patients were assigned to receive HPD-HSCT. Among them, 10 recipients received HSCT from URDs older than 40 years were further excluded. The transplant procedure had been reported previously (Yi Luo et. al. Blood 2014). Briefly, all patients received myeloablative conditioning involving BuCy without total body irradiation. The GVHD prophylaxis consisted of cyclosporin A, methotrexate, and low-dose mycophenolate mofetil. Grafts were granulocyte-colony stimulating factor mobilized peripheral blood stem cells without ex vivo T-cell depletion. Results: The median age of the finally included 146 young recipients was 21 years (range, 15-30 years). Of whom, 67 received HSCT from HPDs and 79 received HSCT from URDs.The median donor age of the HPDs was 46 years (range, 40-53 years), in contrast to 28 years (range, 20-39 years) of the URDs. Engraftment All patients achieved myeloid recovery. The median time and the cumulative 15-day incidences of myeloid engraftment were 12 days (range, 8-16 days) and 97.4% in the URD cohort, and 13 days (range, 8-21 days) and 77.6% in the HPD cohort, respectively. Myeloid recovery in the HPD cohort was significantly delayed compared with URD cohort (P<0.001). Two patients in the HPD cohort experienced primary platelet engraftment failure. The median time and the cumulative 30-day incidences of platelet engraftment were 13 days (range, 6-24 days) and 100% in URDs, and 15 days (range, 6-30 days) and 97.0% in HPDs, respectively. Patients receiving HSCT from HPDs experienced significantly delayed platelet recovery compared with those receiving HSCT from URDs (P<0.001). aGVHD The incidences of grades II-IV aGVHD were 45.5% in the URD cohort and 47.8% in the HPD cohort (P=0.78), respectively. The incidences of grades III-IV aGVHD were 14.3% in the URD cohort and 17.9% in the HPD cohort (P=0.55), respectively. Long-term Outcomes There was a trend of higher 5-year overall survival (OS) and relapse free survival (RFS) rates for patients transplanted from young URDs in comparison with HPDs (OS: 64.4% vs 59.6% (P=0.23) and RFS: 63.2% vs 49.6%; (P=0.20)),respectively. The relapse rate and non-relapse mortality (NRM) rate were comparable between two cohorts. For standard risk patients, a significantly higher 5-year OS and RFS rate were observed for patients transplanted from young URDs compared with HPDs (OS: 76.3% vs 52.7% (P=0.03) and RFS: 73.2% vs 53.8%; (P=0.04)), respectively. The significantly lower survival rate in the HPD cohort to some extent could be explained by the higher NRM rate in the HPD cohort (HPD 30.8% vs URD 13.9%, P=0.07). While for high risk patients, long-term outcomes were comparable between two cohorts. Conclusion: These data favor a young URD over an older-aged HPD for young recipients without siblings in standard risk; while for those in high risk, transplant outcomes were comparable between a young URD and an old-aged HPD. Moreover, myeloid and platelet recovery were significantly delayed in HPD-HSCT compared with URD-HSCT. Disclosures No relevant conflicts of interest to declare.

Unrelated donors for hematopoietic stem cell transplantation in the People's Republic of China

Who is the Better Donor for Young Hematopoietic Transplant Recipients Without Siblings: an Older-Aged Haploidentical Parental Donor or a Young Unrelated Donor?

Impact of HLA High-Resolution Matching on Outcomes of Myeloablative Unrelated Donor Hematopoietic Stem Cell Transplantation in Chinese Population

Outcomes Of Unrelated Donor Hematopoietic Stem Cell Transplantation For Hematological Malignancy: A Single Center'S Experience.

Unrelated Donor Haematopoietic Stem Cell Transplantation for Adult Patients with Haematological Malignancies.

Pediatric hematopoietic stem cell transplantation in China: Data and trends during 1998–2012

Treatment of Childhood Leukemia with Unrelated Donor Allogeneic Bone Marrow Transplantation

Current Status and Development of Hematopoietic Stem Cell Transplantation in China： a Report from Chinese Hematopoietic Stem Cell Transplantation Register Group

Hematopoietic Stem Cell Transplantation in China: Current Status and Prospects.

Related HLA-mismatched/haploidentical Hematopoietic Stem Cell Transplantation Without in Vitro T-cell Depletion: Observations of a Single Chinese Center.

Everyone has a donor: contribution of the Chinese experience to global practice of haploidentical hematopoietic stem cell transplantation

A Review of Hematopoietic Cell Transplantation in China: Data and Trends During 2008–2016

Current status and prospects of hematopoietic stem cell transplantation in China

Progress in unrelated and haploidentical donor hematopoietic stem cell transplantation :improvement of transplantation model and the latest clinical efficacy

Hematopoietic stem cell transplantation activity in China 2019: a report from the Chinese Blood and Marrow Transplantation Registry Group

Haematopoietic stem-cell transplantation in China in the era of targeted therapies: current advances, challenges, and future directions.

Allogeneic Hematopoietic Stem Cell Transplantation in China: Where We Are and Where to Go

The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China—recommendations from the Chinese Society of Hematology

Outcome of 64 Aplastic Anemia Children with Allogenic Hematopoietic Stem Cell Transplant in China: A Report from Chinese Pediatric Group of HSCT

Hematopoietic stem cell transplantation activity in China 2022–2023. The proportions of peripheral blood for stem cell source continue to grow: a report from the Chinese Blood and Marrow Transplantation Registry Group

Xiao-Hui Zhang1, Xiao-Wen Tang3, Yi Luo6, Xiao-Jun Huang1,*, on behalf of the Chinese Blood and Marrow Transplantation Registry Group t